drugset / Trial / NCT07701083
A Study of Eloralintide (LY3841136) in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to learn about safety, tolerability and how well the body processes two different eloralintide solutions. Participation in this study will last about 13 weeks, including screening, inpatient treatment, and follow-up.
Timeline
- Start
- 2026-07
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eloralintide | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.